AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3110105 — intervention group
Group type: EXPERIMENTAL
Intervention: TC3: PCs plus incentives
Number of subjects: 0
Study 3110105 — intervention group
Group type: EXPERIMENTAL
Intervention: TC4: PCs plus incentives and prompts
Number of subjects: 0
Study 29843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming group (Group P, n = 63)
Number of subjects: 189
Study 29843203 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, n = 63)
Number of subjects: 189
Study 29843203 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection group (Group S, n = 63)
Number of subjects: 189
Study 27609624 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling
Number of subjects: 209
Study 27609624 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 209
Study 24307656 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intragraft adenosine infusion (200 μg/min; total dose = 2,000 μg)
Number of subjects: 22
Study 24307656 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 22
Study 23341285 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar Auditory Sensory Training (FAST) protocol
Number of subjects: 0
Study 23341285 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20369508 — intervention group
Group type: EXPERIMENTAL
Intervention: ATS mechanical composite graft
Number of subjects: 30
Study 20369508 — intervention group
Group type: COMPARATOR
Intervention: SJM mechanical composite graft
Number of subjects: 30
Study 20369508 — intervention group
Group type: COMPARATOR
Intervention: Sorin mechanical composite graft
Number of subjects: 30
Study 18490173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track treatment regimen (preoperative fasting 2h, patient controlled epidural analgesia)
Number of subjects: 0
Study 18490173 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment regimen (preoperative fasting 6h, patient controlled analgesia)
Number of subjects: 0
Study 18490173 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track treatment regimen
Number of subjects: 0
Study 18490173 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment regimen
Number of subjects: 0
Study 16437370 — intervention group
Group type: EXPERIMENTAL
Intervention: VPRG (vagus nerve preserved and reconstruction of gastric funds)
Number of subjects: 68
Study 16437370 — intervention group
Group type: EXPERIMENTAL
Intervention: VPRG
Number of subjects: 68
Study 16437370 — intervention group
Group type: COMPARATOR
Intervention: VSNG (vagus nerve severed and no reconstruction of gastric funds)
Number of subjects: 68
Study 14760891 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant viral phenotype method
Number of subjects: 300
Study 14760891 — intervention group
Group type: COMPARATOR
Intervention: Virtual phenotype (genotyping interpretation system)
Number of subjects: 300
Study 10382694 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 990
Study 10382694 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 990
Study 8967601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam p.o. (Dormicum)
Number of subjects: 47
Study 8967601 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally 30 min before RBA
Number of subjects: 47
Study 1319542 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg hANP-(95-126) (Urodilatin)
Number of subjects: 32
Study 1319542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 micrograms/kg hANP-(95-126) (Urodilatin)
Number of subjects: 32
Study 1319542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1319542 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP
Number of subjects: 32
Study 6379784 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific immunotherapy (aqueous suspension of heat killed mycobacterium smegmatis, administered subcutaneously once a month)
Number of subjects: 219
Study 6379784 — intervention group
Group type: COMPARATOR
Intervention: Control group (no other treatment following excision)
Number of subjects: 219
Study 31477562 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean-ketogenic diet (MMKD)
Number of subjects: 17
Study 31477562 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association Diet (AHAD)
Number of subjects: 17
Study 31477562 — intervention group
Group type: EXPERIMENTAL
Intervention: MMKD
Number of subjects: 17
Study 31477562 — intervention group
Group type: COMPARATOR
Intervention: AHAD
Number of subjects: 17
Study 29965991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral nerve block (PNB) with 10 mL prilocaine 1% and 10 mL ropivacaine 0.2%
Number of subjects: 30
Study 29965991 — intervention group
Group type: COMPARATOR
Intervention: Analgosedation (AS) with midazolam combined with s-ketamine or fentanyl
Number of subjects: 30
Study 26902832 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukmijihwang-tang (YMJ) administered at 3g, three times per day for 8 weeks
Number of subjects: 96
Study 26902832 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 3g, three times per day for 8 weeks
Number of subjects: 96
Study 25158865 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor (sitagliptin 200 mg by mouth)
Number of subjects: 17
Study 25158865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25158865 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 17
Study 25158865 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 17
Study 25158865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 17
Study 25158865 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and BNP
Number of subjects: 17
Study 21574670 — intervention group
Group type: COMPARATOR
Intervention: Parental monitoring
Number of subjects: 256
Study 21574670 — intervention group
Group type: COMPARATOR
Intervention: Prematriculation social modeling among peers
Number of subjects: 256
Study 21574670 — intervention group
Group type: COMPARATOR
Intervention: Prematriculation descriptive norms
Number of subjects: 256
Study 21574670 — intervention group
Group type: COMPARATOR
Intervention: Parental drinking permissiveness
Number of subjects: 256
Study 21574670 — intervention group
Group type: COMPARATOR
Intervention: Social modeling among peers
Number of subjects: 256
Study 20634635 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing (modified Mason's breathing technique), 3 times a day for 3 days
Number of subjects: 60
Study 17216336 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg CS‐706 once daily
Number of subjects: 160
Study 17216336 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg CS‐706 once daily
Number of subjects: 160
Study 17216336 — intervention group
Group type: COMPARATOR
Intervention: 500 mg naproxen twice daily
Number of subjects: 160
Study 16311656 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients
Number of subjects: 27
Study 16311656 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 27
Study 11952197 — intervention group
Group type: EXPERIMENTAL
Intervention: Same context as extinction
Number of subjects: 78
Study 11952197 — intervention group
Group type: COMPARATOR
Intervention: Different context
Number of subjects: 78
Study 11952197 — intervention group
Group type: EXPERIMENTAL
Intervention: Different context with E-cue
Number of subjects: 78
Study 9854762 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative approach with clinical examination and education in a 'mini back school'.
Number of subjects: 489
Study 9854762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 489
Study 7793169 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost (1 mg) as a vaginal suppository in 12 hour intervals
Number of subjects: 68
Study 7793169 — intervention group
Group type: COMPARATOR
Intervention: Dinoprost (500 micrograms) in a tylose-gel in 6-8 hour intervals
Number of subjects: 68
Study 2193840 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg frusemide/2.5 mg amiloride
Number of subjects: 71
Study 2193840 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg cyclopenthiazide/8.1 mmol sustained release potassium
Number of subjects: 71
Study 842487 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea supplementation (4 g of nitrogen)
Number of subjects: 7
Study 842487 — intervention group
Group type: COMPARATOR
Intervention: Opaque-2 corn (6 g of nitrogen)
Number of subjects: 7
Study 31332449 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory method
Number of subjects: 237
Study 31332449 — intervention group
Group type: COMPARATOR
Intervention: ERC algorithm
Number of subjects: 237
Study 29199342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (receiving interventions)
Number of subjects: 153
Study 29199342 — intervention group
Group type: COMPARATOR
Intervention: Group B (no interventions)
Number of subjects: 153
Study 25743742 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Professional education program (5 sessions, 16 content items for 2 weeks)
Number of subjects: 86
Study 23415616 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based physical activity intervention
Number of subjects: 285
Study 23415616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 21270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation 5 μg/d
Number of subjects: 144
Study 21270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation 10 μg/d
Number of subjects: 144
Study 21270380 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation 6.3 μg/d
Number of subjects: 144
Study 21270380 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D(3) supplementation 0 μg/d (placebo)
Number of subjects: 144
Study 19011511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome infusion (VSLI) at 2.0 mg/m infused over 1 hour every 2 weeks (one cycle)
Number of subjects: 27
Study 19011511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome infusion (VSLI)
Number of subjects: 27
Study 16414124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (n=16)
Number of subjects: 46
Study 16414124 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (n=15)
Number of subjects: 46
Study 16414124 — intervention group
Group type: COMPARATOR
Intervention: 9% NaCl (saline) (control group, n=15)
Number of subjects: 46
Study 12923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IEx) at 50% and 70% VO2peak
Number of subjects: 9
Study 12923641 — intervention group
Group type: COMPARATOR
Intervention: Continuous Exercise (CEx) at 70% VO2peak
Number of subjects: 9
Study 12923641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Exercise (IEx) 60sE:60sR at 70% VO2peak
Number of subjects: 9
Study 12923641 — intervention group
Group type: COMPARATOR
Intervention: Continuous Exercise (CEx) and Intermittent Exercise (IEx) at 50% VO2peak
Number of subjects: 9
Study 10883560 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy
Number of subjects: 143
Study 9020419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% morphine HCl nasal challenge
Number of subjects: 5
Study 9020419 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace trial with bronchodilator and placebo
Number of subjects: 5
Study 9020419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and bronchial challenge with 0.5% morphine HCl
Number of subjects: 5
Study 9020419 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 5
Study 1411923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis platinum (Cis PII) 100 mg/m2 i.v. followed by 6 Gy irradiation in two fractions on days 3 and 5, five cycles at 21 days interval.
Number of subjects: 19
Study 1411923 — intervention group
Group type: COMPARATOR
Intervention: Three fractions per day radiotherapy regimen (3 FRT) in split-course (two series of 22.50 Gy in 15 fractions, five days separated by two weeks rest).
Number of subjects: 19
Study 3871251 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple sulfonamide combined with either phenoxymethyl penicillin or benzathine and procaine penicillin G (IM)
Number of subjects: 948
Study 3871251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl penicillin and cyclacillin alone
Number of subjects: 948
Study 3871251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor and trimethoprim-sulfamethoxazole
Number of subjects: 948
Study 31571070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic contact lenses (Omafilcon A)
Number of subjects: 18
Study 31571070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic contact lens (Hexafocon A)
Number of subjects: 18
Study 31571070 — intervention group
Group type: COMPARATOR
Intervention: Control (no contact lens)
Number of subjects: 18
Study 30860055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration first pass
Number of subjects: 270
Study 30860055 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever first line
Number of subjects: 270
Study 30860055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 270
Study 29228950 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 0
Study 29228950 — intervention group
Group type: COMPARATOR
Intervention: salmeterol/fluticasone (SFC)
Number of subjects: 0
Study 25521661 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Connect Online (PCO) intervention, a 3-hour workshop for creation of personal websites with a blog function.
Number of subjects: 88
Study 25521661 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (not explicitly detailed in outcomes).
Number of subjects: 88
Study 24708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 200
Study 24708349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 22466866 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcasted exemplars
Number of subjects: 0
Study 20953168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL lidocaine plus dummy lingual injection (LB)
Number of subjects: 31
Study 20953168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mL lidocaine (LBL)
Number of subjects: 31
Study 20953168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL articaine plus dummy lingual injection (AB)
Number of subjects: 31
Study 20953168 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mL articaine (ABL)
Number of subjects: 31
Study 20953168 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 31
Study 20953168 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 31
Study 17437743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (defined as baseline hematocrit <36%)
Number of subjects: 6360
Study 17437743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in subjects with CKD (baseline GFR ≤60 ml/min/1.73 m²)
Number of subjects: 6360
Study 17437743 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in subjects without CKD
Number of subjects: 6360
Study 16353881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate 1%
Number of subjects: 68
Study 16353881 — intervention group
Group type: COMPARATOR
Intervention: Rimexolone 1%
Number of subjects: 68
Study 12225796 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (various doses)
Number of subjects: 139
Study 12225796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 12225796 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (minimally effective dose)
Number of subjects: 139
Study 12179676 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administered at the end of the second stage of labor
Number of subjects: 130
Study 7784413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (CAB 0.5‐1 mg twice weekly)
Number of subjects: 120
Study 7784413 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (BRC 2.5‐5 mg twice daily)
Number of subjects: 120
Study 2353171 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release, enteric-coated tablet of mesalazine (Claversal)
Number of subjects: 13
Study 383174 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrinolytic substance (AMCHA)
Number of subjects: 30
Study 383174 — intervention group
Group type: EXPERIMENTAL
Intervention: Bothrops Jararaca venom extract
Number of subjects: 30
Study 383174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29618272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified pasteurized donor human milk (PDHM)
Number of subjects: 80
Study 29618272 — intervention group
Group type: COMPARATOR
Intervention: Unfortified pasteurized donor human milk (PDHM)
Number of subjects: 80
Study 27052039 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous cyanoacrylate (Sapheon Venaseal Closure System)
Number of subjects: 29
Study 25906561 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (resuscitation and tranquilization technique) applied to specific acupuncture points (Shenting, Shuigou, Sishencong, Baihui, Feng-chi) once daily, 6 times a week for 8 weeks.
Number of subjects: 40
Study 25906561 — intervention group
Group type: COMPARATOR
Intervention: Deanxit (oral administration, 1 tablet in the morning and lunchtime each day for 8 weeks).
Number of subjects: 40
Study 23722881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 3746
Study 23722881 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3746
Study 23722881 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 3746
Study 22192566 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation
Number of subjects: 46
Study 22192566 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive listening
Number of subjects: 46
Study 18954875 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1398
Study 18954875 — intervention group
Group type: COMPARATOR
Intervention: Pooled comparators (citalopram, duloxetine, paroxetine)
Number of subjects: 1398
Study 17905358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentionally treated chocolate (three different techniques)
Number of subjects: 62
Study 17905358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentionally treated chocolate (for individuals consuming less than 3.2 ounces of chocolate per week)
Number of subjects: 62
Study 17905358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentionally treated chocolate (general mood factors)
Number of subjects: 62
Study 17905358 — intervention group
Group type: COMPARATOR
Intervention: Untreated chocolate (placebo control)
Number of subjects: 62
Study 16304902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 5
Study 16304902 — intervention group
Group type: EXPERIMENTAL
Intervention: MTOPS study
Number of subjects: 5
Study 12166883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation
Number of subjects: 370
Study 12166883 — intervention group
Group type: COMPARATOR
Intervention: Fitness assessment
Number of subjects: 370
Study 10628768 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease with acute rejection
Number of subjects: 1339
Study 10628768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection
Number of subjects: 1339
Study 10628768 — intervention group
Group type: EXPERIMENTAL
Intervention: Older donor age
Number of subjects: 1339
Study 10628768 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV disease
Number of subjects: 1339
Study 10628768 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejection with CMV disease
Number of subjects: 1339
Study 10628768 — intervention group
Group type: COMPARATOR
Intervention: No acute rejection with CMV disease
Number of subjects: 1339
Study 7883938 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulorrhaphy
Number of subjects: 39
Study 7883938 — intervention group
Group type: COMPARATOR
Intervention: Capsulectomy
Number of subjects: 39
Study 1697916 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy of the prostatic urethra
Number of subjects: 49
Study 1697916 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 49
Study 380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg/70 kg
Number of subjects: 7
Study 380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 10 mg/70 kg
Number of subjects: 7
Study 380610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 60 mg/70 kg
Number of subjects: 7
Study 380610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30961631 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapleless bypass surgery (LOAGB-OSPAN)
Number of subjects: 0
Study 30961631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gastric bypass surgery (LMGB-OAGB)
Number of subjects: 0
Study 30961631 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical weight loss therapy (hypocaloric diet -500 kcal/day)
Number of subjects: 0
Study 29389246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (Az; 10 mg/kg) plus intravenous dobutamine (Dob) infusion (2-5 μg·kg-1·min-1)
Number of subjects: 11
Study 29389246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin (Indo; 100 mg)
Number of subjects: 11
Study 29389246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 27113231 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure-based cognitive behaviour therapy (ICBT) for 12 weeks
Number of subjects: 158
Study 27113231 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered behavioural stress management (IBSM) for 12 weeks
Number of subjects: 158
Study 24662777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day, n = 24)
Number of subjects: 72
Study 24662777 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day, n = 24)
Number of subjects: 72